Biomarin Pharmaceutical Inc (BMRN)

BMRN (NASDAQ:Drugs) EQUITY
$129.37
neg -3.80
-2.90%
Today's Range: 128.67 - 136.85 | BMRN Avg Daily Volume: 1,309,900
Last Update: 08/31/15 - 3:59 PM EDT
Volume: 1,156,418
YTD Performance: 47.32%
Open: $134.05
Previous Close: $133.18
52 Week Range: $65.91 - $151.75
Oustanding Shares: 161,094,110
Market Cap: 21,085,608,058
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 10 11 11
Moderate Buy 1 1 1 1
Hold 3 3 3 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.50 1.50 1.47 1.36
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -96.24
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-96.24 0.00 25.43
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.55% 91.30% 247.28%
GROWTH 12 Mo 3 Yr CAGR
Revenue 36.90 0.70 0.19
Net Income 0.00 1.49 0.00
EPS 0.00 0.92 0.00
Earnings for BMRN:
EBITDA -0.10B
Revenue 0.75B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $-0.66 $-0.73 $-2.34 $-1.68
Number of Analysts 10 9 9 11
High Estimate $-0.52 $-0.59 $-2.06 $-1.10
Low Estimate $-1.02 $-1.10 $-2.90 $-2.40
Prior Year $-0.16 $-0.30 $-0.77 $-2.34
Growth Rate (Year over Year) -314.38% -144.07% -203.61% 28.18%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Which means interest rate hikes are being built into prices.
The bulls can show them around the place.
Coal and renewables could both react as political and legal battles ensue.
BioMarin's chart has a well-defined uptrend line and shows great relative strength.

Biotech Stocks Are Booming Real Money Pro($)

I like BioMarin because it has more upside and solid Relative Strength.
Bearish
Jun 19, 2015 | 7:04 AM EDT
BMRN was downgraded from Outperform to Neutral, Robert Baird said. Valuation call, based on a $133 price target.  
Bullish
Jun 05, 2015 | 7:18 AM EDT
BMRN was initiated with an Overweight rating, Barclays said. $150 price target. Company has strong operating momentum with major pipeli...
Sector may not be as bulletproof as we thought.
Many of these stocks are off to the races.

Columnist Conversations

The OIH(Oil Service ETF)is up another 2.5% this afternoon and is now up over 21% from last Monday's close...
Again for emphasis. An important top was likely established in the first half of 2015. Last week might have be...
A few weeks ago I mentioned the massive lockup release to come, on Sept 20 BABA will have over 1.6 bill shares...
I've done quite a bit of work on $FCX and other commodity/mining stocks in the last few months SeeStick With R...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.